Retrospective comparison of mesenchymal stromal cells and antithymocyte globulin as second-line therapy for acute graft-versus-host disease. (PubMed, Cytotherapy) - Sep 3, 2026 - "As a second-line treatment for first-line steroid-refractory acute GVHD, ruxolitinib was proven to be significantly more effective than control therapies (nine commonly used therapy options) in a prospective, randomized trial...In conclusion, this retrospective study demonstrated that the ORR based on whole body assessment and the ORR based on gastrointestinal tract stage assessment were both significantly higher with MSC therapy than with ATG therapy. However, prospective, randomized, controlled trials are necessary for a more accurate comparison."
Journal • Retrospective data • Acute Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Transplantation
|
|
Atsushi Wake; Hirohisa Nakamae; Junya Kanda; Keisuke Kataoka; Ken Tabuchi; Maho Sato; Makoto Murata; Makoto Onizuka; Masahito Tokunaga; Moeko Hino; Naoyuki Uchida; Noriko Doki; Satoshi Yoshihara; Seitaro Terakura; Shuichi Ota; Takahiro Fukuda; Takanori Teshima; Yasuo Mori; Yoshiko Atsuta
|